Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)
Publication
, Journal Article
McMurray, JJV; Packer, M; Desai, AS; Gong, J; Lefkowitz, MP; Rizkala, AR; Rouleau, J; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR
Published in: European Journal of Heart Failure
September 2013
Duke Scholars
Published In
European Journal of Heart Failure
DOI
EISSN
1879-0844
ISSN
1388-9842
Publication Date
September 2013
Volume
15
Issue
9
Start / End Page
1062 / 1073
Publisher
Oxford University Press (OUP)
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., … Zile, M. R. (2013). Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF). European Journal of Heart Failure, 15(9), 1062–1073. https://doi.org/10.1093/eurjhf/hft052
McMurray, John J. V., Milton Packer, Akshay S. Desai, Jim Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean Rouleau, et al. “Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF).” European Journal of Heart Failure 15, no. 9 (September 2013): 1062–73. https://doi.org/10.1093/eurjhf/hft052.
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF). European Journal of Heart Failure. 2013 Sep;15(9):1062–73.
McMurray, John J. V., et al. “Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF).” European Journal of Heart Failure, vol. 15, no. 9, Oxford University Press (OUP), Sept. 2013, pp. 1062–73. Crossref, doi:10.1093/eurjhf/hft052.
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF). European Journal of Heart Failure. Oxford University Press (OUP); 2013 Sep;15(9):1062–1073.
Published In
European Journal of Heart Failure
DOI
EISSN
1879-0844
ISSN
1388-9842
Publication Date
September 2013
Volume
15
Issue
9
Start / End Page
1062 / 1073
Publisher
Oxford University Press (OUP)
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology